Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index; 2 of the 77 sources its claims cite were checked for support.
Abstract
Leading biological hypotheses propose that biological changes may underlie major depressive disorder onset and relapse/recurrence. Here, we investigate if there is prospective evidence for biomarkers derived from leading theories. We focus on neuroimaging, gastrointestinal factors, immunology, neurotrophic factors, neurotransmitters, hormones, and oxidative stress. Searches were performed in Pubmed, Embase and PsychInfo for articles published up to 06/2019. References and citations of included articles were screened to identify additional articles. Inclusion criteria were having an MDD diagnosis as outcome, a biomarker as predictor, and prospective design search terms were formulated accordingly. PRISMA guidelines were applied. Meta-analyses were performed using a random effect model when three or more comparable studies were identified, using a random effect model. Our search resulted in 67,464 articles, of which 75 prospective articles were identified on: Neuroimaging (N = 24), Gastrointestinal factors (N = 1), Immunology (N = 8), Neurotrophic (N = 2), Neurotransmitters (N = 1), Hormones (N = 39), Oxidative stress (N = 1). Meta-analyses on brain volumes and immunology markers were not significant. Only cortisol (N = 19, OR = 1.294,p = 0.024) showed a predictive effect on onset/relapse/recurrence of MDD, but not on time until MDD onset/relapse/recurrence. However, this effect disappeared when studies including participants with a baseline clinical diagnosis were removed from the analyses. Other studies were too heterogeneous to compare. Thus, there is a lack of evidence for leading biological theories for onset and maintenance of depression. Only cortisol was identified as potential predictor for MDD, but results are influenced by the disease state. High-quality (prospective) studies on MDD are needed to disentangle the etiology and maintenance of MDD.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found scarce prospective evidence that leading biological biomarkers predict major depressive disorder onset, relapse, or recurrence. Only cortisol showed a small predictive effect, but it was confounded by baseline clinical depression, study quality, and possible publication bias.
Key findings
- From 67,464 screened articles, 75 prospective studies were identified: neuroimaging (N = 24), gastrointestinal factors (N = 1), immunology (N = 8), neurotrophic factors (N = 2), neurotransmitters (N = 1), hormones (N = 39), and oxidative stress (N = 1).
- Meta-analyses on brain volumes and immunology markers were not significant. Cortisol was the only significant predictor across comparable studies (N = 19, OR = 1.294, 95% CI [1.035–1.616], p = 0.024), but not for time until MDD onset/relapse/recurrence (HR = 1.011, 95% CI [0.963–1.040], p = 0.447).
- The cortisol effect disappeared when studies including participants with a baseline clinical MDD diagnosis were removed; it also became nonsignificant after removing outliers or low-quality studies, and publication-bias correction led to a nonsignificant effect.
- Only 38 studies excluded participants with baseline clinical MDD diagnosis, and most other biomarker findings were too heterogeneous or incidental to meta-analyze.
Methods
- Systematic review and meta-analysis following PRISMA, with searches in PubMed, Embase, and PsychInfo up to June 2019; inclusion required a prospective design, MDD diagnosis as outcome, and a biomarker from leading biological models as predictor.
- Random-effects meta-analyses were performed when three or more comparable studies were available, using odds ratio or risk ratio as summary effects; heterogeneity was assessed with Q-test and I², with sensitivity analyses, moderator analyses, and publication-bias assessment.
- The review included 75 prospective studies; 3,267 participants developed MDD over follow-up (median 3 years), and mean study quality score was 6.3 (median 6, range 3–9).
Limitations
- The paper states that included studies were often of poor quality, had small numbers of MDD cases at follow-up, and that neuroimaging studies used smaller samples than immunology and hormone studies.
- The authors did not correct for multiple testing; they note that such a correction would eliminate the cortisol effect, suggesting it may be a false positive.
- The paper states that heterogeneity was marked, many nonsignificant studies did not report sufficient data for meta-analysis, and this may have inflated odds ratios; results should be interpreted with caution.
- Evident from the text: many biomarker domains had fewer than three comparable studies or highly heterogeneous methods, precluding meta-analysis and limiting conclusions about most proposed biomarkers.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Flow Diagram of systematic search for prospective studies of MDD overall biological searches combined [24]. See Supplementary material for flow charts per search](https://figures.cochat.ai/paper-figures/09d3e935c0ab467bb980cb86433fcb2a/prospective-biomarkers-of-major-depressive-disorder-a-systematic-review-and-meta-figure-1.jpg)
![Fig. 2 Forest plot of a meta-analysis on studies investigating measures of cortisol before MDD onset, relapse or recurrence. Charles et al. [42] and Cosgriff et al. [48] are identified as outliers, and excluding them from analysis resulted in a nonsignificant effect](https://figures.cochat.ai/paper-figures/10f7f71adb7d404685e9181a0a6a0a76/prospective-biomarkers-of-major-depressive-disorder-a-systematic-review-and-meta-figure-2.jpg)
Verification
Claims the paper makes
1 Valid · 4 Not valid · 43 Not checked · 86 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“No significant predictive value of the amygdala volume was found in three studies investigating two unique samples [53,54,74].”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Neuroimaging
What the sources say
- Not checked yetcites [53] Frodl T, Meisenzahl EM, Zetzsche T, Höhne T, Banac S, Schorr C, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004;65:492–9.* source
- Supportedcites [54] Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T, et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci. 2008;33:423–30.* source
Our copy of Frodl et al. (2008) reports exactly the null predictive finding attributed to it: in the Results section (p. 426) 'Amygdala volume was not affected by remission status (F1–26 = 0.16, p = 0.69)' and patients with larger baseline amygdala volumes 'did not have significantly lower HDRS scores at 1, 2 and 3 years (F1–25 = 0.74, p = 0.40)', with no significant correlation between HDRS scores and amygdala volumes at baseline, discharge or 3-year follow-up. The aggregation into 'three studies investigating two unique samples' is the citing authors' synthesis across references 53, 54 and 74 and is not something this single source is asked to carry; the part attributed to this paper — a study showing no significant predictive value of amygdala volume for clinical outcome in major depression — is stated here. (LLM, conf=0.88)
- Supportedcites [74] Little K, Olsson CA, Whittle S, Youssef GJ, Byrne ML, Simmons JG, et al. Association between serotonin transporter genotype, brain structure and adolescent-onset major depressive disorder: a longitudinal prospective study. Transl Psychiatry. 2014;4:e445.* source
Our copy of Little et al. (2014) reports exactly this null finding: the Results state that '5-HTTLPR did not predict left or right amygdala volume ... nor were these volumes related to risk for MDD onset' (Results, mediation/ROI section), and the Discussion opens by noting 'the lack of evidence supporting amygdala volume as an intermediate phenotype between serotonin transporter gene and depression onset' (Discussion). The 'three studies investigating two unique samples' aggregation spans the other two citations in the sentence and is the citing authors' framing, not something this source must state; the part attributed to this paper — a prospective adolescent study finding no significant predictive value of amygdala volume for depression onset — is fully supported. (LLM, conf=0.85)
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, due to overlap in study samples and heterogeneity in methods applied (e.g.tasks, regions of interest), meta-analysis could only be performed on some hippocampus, amygdala and frontal brain area volumes (see Table 1 and Supplementary Fig. 2).”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Neuroimaging
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Incidental structural MRI studies reported that both smaller and larger insula volume was significantly related to MDD development in two studies [51,91].”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Neuroimaging
What the sources say
- Not checked yetcites [51] Foland-Ross LC, Sacchet MD, Prasad G, Gilbert B, Thompson PM, Gotlib IH. Cortical thickness predicts the first onset of major depression in adolescence. Int J Dev Neurosci. 2015;46:125–31.* source
- Not checked yetcites [91] Rao U, Chen L-A, Bidesi AS, Shad MU, Thomas MA, Hammen CL. Hippocampal changes associated with early-life adversity and vulnerability to depression. Biol Psychiatry. 2010;67:357–64.* source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 75 prospective articles were identified on: Neuroimaging (N = 24), Gastrointestinal factors (N = 1), Immunology/inflammation (N = 8), Neurotrophic (N = 2), Neurotransmitters (N = 1), Hormones (N = 39), and Oxidative stress (N = 1).”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Search results and quality assessment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“These studies showed that MDD development was predicted by: lower activity in the frontal lobe in various contexts ( [39] reward task lossgain contrast [83]; rest [71,82]; go/nogo task, errors; [31] pre-vs posttryptophan depletion), higher activity in the insula ( [99] sentence completion increasing in difficulty), higher subgenual anterior cingulate cortex (ACC) temporal and striatal connectivity”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Neuroimaging
What the sources say
- Not checked yetcites [39] Bress JN, Foti D, Kotov R, Klein DN, Hajcak G. Blunted neural response to rewards prospectively predicts depression in adolescent girls. Psychophysiology. 2013;50:74–81.* source
- Not checked yetcites [83] Nusslock R, Shackman AJ, Harmon-Jones E, Alloy LB, Coan JA, Abramson LY. Cognitive vulnerability and frontal brain asymmetry: common predictors of first prospective depressive episode. J Abnorm Psychol. 2011;120:497–503.* source
- Not checked yetcites [71] Langenecker SA, Jenkins LM, Stange JP, Chang Y-S, DelDonno SR, Bessette KL, et al. Cognitive control neuroimaging measures differentiate between those with and without future recurrence of depression. Neuroimage Clin. 2018;20:1001–9.* source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
62 more claims
Create a free account to see all 134 claims and to verify the 75 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 31
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent research has shown a link between decreased hippocampal neurogenesis and low levels of BDNF and glial-derived neurotrophic factor (GDNF) in the brains of depressed individuals. 145”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [145]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These concerns include overreliance on cross-sectional methodologies, a lack of consensus on what constitutes recurrence, and grouping all individuals with MDD together instead of differentiating subgroups using key characteristics of the disorder (e.g., single verse recurrent episodes) [3, 6–8].”
From Fear of depression recurrence among individuals with remitted depression: a qualitative interview study (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The dataset used in this study comes from a systematic review-based meta-analysis focusing on the evidence for leading psychological and biological theories on the onset, maintenance, and relapse of depressive disorders (Brouwer et al., 2019; Kennis et al., 2020; Fu et al., 2021).”
From Active learning-based systematic reviewing using switching classification models: the case of the onset, maintenance, and relapse of depressive disorders (2023) · cites this paper as Kennis et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“A review exploring prospective biomarkers (e.g., hormones, oxidative stress) in MDD recurrence found that cortisol significantly increased odds for MDD onset and relapse [6].”
From Fear of depression recurrence among individuals with remitted depression: a qualitative interview study (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“It is crucial to highlight the results in a recent meta-analysis, which found that cortisol was the only biological marker that increased the odds for both the onset and relapse/recurrence of MDD [35].”
From Stress and serum cortisol levels in major depressive disorder: a cross-sectional study (2020) · cites this paper as [35]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Immunology
“↑ heat-shock protein 70, 3nitrotyrosine, protein carbonyl, and lipid peroxidation ↓BDNF”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Oxidative stress
“No significant differences between these groups were found for protein carbon and thiol content.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > HPA axis
“OR = 1.919”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > HPA axis
“95% CI [1.072 1.231]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“19 studies had a very low risk of bias (>6 quality score), 26 studies had some risk of bias (5-6 quality score), and 8 studies had high risk of bias (4 or lower quality score).”
§ Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis > Search results and quality assessment
Reported 75 · recomputed 53
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 2×
“Methods Search process and study selection The study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA [24]; see Appendices A and B for search terms and flow charts and Appendix C for PRISMA checklist).”
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“Publication bias was also assessed using Egger’s test for asymmetry [28] of the funnel plot and Duval and Tweedie’s trim and fill procedure [29].”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity was assessed with the Qtest and I(2) statistic [27].”
MethodDuval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099 · cited 1×
“Publication bias was also assessed using Egger’s test for asymmetry [28] of the funnel plot and Duval and Tweedie’s trim and fill procedure [29].”
MethodKessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052 · cited 1×
“Introduction Major depressive disorder (MDD) is a disabling disorder that is amongst the most prevalent mental health disorders worldwide [1, 2] and is highly recurrent [3–5].”
BackgroundGRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681 · cited 1×
“The quality of included studies was assessed by two team members according to a minimally adjusted version of the GRADE guidelines on study level [25].”
MethodDepression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070 · cited 1×
“Introduction Major depressive disorder (MDD) is a disabling disorder that is amongst the most prevalent mental health disorders worldwide [1, 2] and is highly recurrent [3–5].”
Background
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“145 Under normal conditions, astrocytes release various nutrients and cytokines.”
BackgroundThe serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
“[21], we devised six criteria relevant to the included studies: whether a unified analysis was conducted on original data; whether confounding by antidepressant use was adequately addressed; whether outcomes were pre-specified; whether results were consistent or heterogeneity was adequately addressed if present; wheth…”
InfluentialMarx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“High salivary cortisol levels in mornings can prospectively predict risk for MDD onset, suggesting cortisol could also act as a potential biomarker for MDD 96,97 .”
Comorbid depression in medical diseases
Gold, S. M., Köhler-Forsberg, O., Moss-Morris, R., Mehnert, A., Miranda, J. J., Bullinger, M., Steptoe, A., Whooley, M. A., & Otte, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0200-2 · Cited by 534
Zajkowska, Z., Gullett, N., Walsh, A., Zonca, V., Pedersen, G. A., Souza, L., Kieling, C., Fisher, H. L., Kohrt, B. A., & Mondelli, V. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105625 · Cited by 228
“A compelling body of evidence implicates dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in the pathophysiology of MDD in adulthood (Kennis et al., 2020; Stetler and Miller, 2011).”
BackgroundResultInfluential
Metadata
- Authors
- Kennis, M., Gerritsen, L., van Dalen, M., Williams, A., Cuijpers, P., & Bockting, C.
- Affiliations
- Utrecht University (NL)
- Amsterdam Public Health (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Bockting, Claudi
- Venue
- Molecular Psychiatry
- Published
- 2019-11-19
- Volume
- 25
- Issue
- 2
- Pages
- 321-338
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC6974432
- OpenAlex
- W2990461417
- Semantic Scholar
- d1f9cb4cbfa3b5f569fe2d5103c60226685b23b2
- Cited by
- 435
- References
- 122
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 74 · 2023: 76 · 2022: 69 · 2021: 66 · 2020: 24 · 2019: 1
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Netherlands Institute for Advanced Study in the Humanities and Social Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- major depressive disorder, biomarkers, depression onset, relapse and recurrence, cortisol, neuroimaging, neurotrophic factors, neurotransmitters, hormones, oxidative stress, brain volume, etiology of depression
- MeSH terms
- Major Depressive Disorder, Humans, Hydrocortisone, Prospective Studies, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-019-0585-z
- The paper
- Kennis, M., Gerritsen, L., van Dalen, M., Williams, A., Cuijpers, P., & Bockting, C. (2020). Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0585-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.